Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vivian M. Liu"'
Autor:
Jasmine Naru, Megan Othus, ChenWei Lin, Melinda A. Biernacki, Marie Bleakley, Thomas R. Chauncey, Harry P. Erba, Min Fang, Matthew P. Fitzgibbon, Phillip R. Gafken, Richard G. Ivey, Jacob J. Kennedy, Travis D. Lorentzen, Soheil Meshinchi, Anna Moseley, Era L. Pogosova‐Agadjanyan, Vivian M. Liu, Jerald P. Radich, Uliana J. Voytovich, Pei Wang, Jeffrey R. Whiteaker, Cheryl L. Willman, Feinan Wu, Amanda G. Paulovich, Derek L. Stirewalt
Publikováno v:
eJHaem, Vol 5, Iss 6, Pp 1243-1251 (2024)
Abstract Introduction Acute myeloid leukemia (AML) remains one of the deadliest hematopoietic malignancies. A better understanding of the molecular biology governing AML may lead to improved risk stratification and facilitate the development of novel
Externí odkaz:
https://doaj.org/article/18d3b04e042e48a2a897b435a871a0b6
Autor:
William J. Israelsen, Aaron M. Hosios, Vivian M. Liu, Matthew G. Vander Heiden, Zhaoqi Li, Andrea J. Howell
Publikováno v:
FEBS Lett
Mammalian pyruvate kinase catalyzes the final step of glycolysis, and its M2 isoform (PKM2) is widely expressed in proliferative tissues. Mutations in PKM2 are found in some human cancers; however, the effects of these mutations on enzyme activity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0970629b887c99ae214991e1975c7774
https://doi.org/10.1002/1873-3468.13648
https://doi.org/10.1002/1873-3468.13648
Publikováno v:
Brain Pathology. 25:781-783
The M2 isoform of pyruvate kinase is expressed preferentially in cancer cells over other pyruvate kinase isoforms. PKM2 is unique in its ability to be regulated allosterically by nutrients and growth signaling pathways, allowing cells to adapt their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::888b5553b3a33ef80cf3937e45fdb766
https://doi.org/10.1111/bpa.12311
https://doi.org/10.1111/bpa.12311
Autor:
Vamsi K. Mootha, John G. Doench, Shuqiang Li, Alexis Jourdain, Aina Zurita Martinez, Giulia Notarangelo, Matthew S. Davids, Cory M. Johannessen, María Hernández-Sánchez, Romain Guieze, Philip A. Thompson, Zacchary Cartun, Kaitlyn Baranowski, Ozan Aygün, Sun Jing, Wade Harper, Catherine J. Wu, Donna Neuberg, Heo Jin-Mi, Steven A. Carr, Ignaty Leshchiner, Federica Piccioni, Daniel Rosebrock, Vivian M. Liu, Jennifer R. Brown, Dimitri Livitz, Christopher J. Ott, Gad Getz, William G. Wierda, Anthony Letai
Publikováno v:
Blood. 132:893-893
The FDA-approval of potent targeted therapies has led to great changes in the therapeutic landscape of chronic lymphocytic leukemia (CLL). As a key example, venetoclax, a first-in-class BCL-2 inhibitor, leads to response in about 80% of patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ded7c5d267496683740c598a9ad0618
https://doi.org/10.1182/blood-2018-99-118604
https://doi.org/10.1182/blood-2018-99-118604